Vulnerable Plaque Diagnosis, Treatment: Is Enrollment “Impossible”?
This article was originally published in The Gray Sheet
Executive Summary
Diagnostic modalities and therapies for vulnerable plaque should be tested simultaneously in one clinical trial to ensure the enrollment size is manageable, according to cardiac researcher James Muller, MD, Massachusetts General Hospital
You may also be interested in...
Optical Imaging Indicates Multifocal Approach To Coronary Lesion Treatment
Systematic treatment of coronary inflammation should accompany localized treatment of vulnerable plaques in prevention strategies for myocardial infarction, according to an analysis by Massachusetts General Hospital's Wellman Center for Photomedicine
Optical Imaging Indicates Multifocal Approach To Coronary Lesion Treatment
Systematic treatment of coronary inflammation should accompany localized treatment of vulnerable plaques in prevention strategies for myocardial infarction, according to an analysis by Massachusetts General Hospital's Wellman Center for Photomedicine
DES For Vulnerable Plaque: Consensus Elusive With Current Imaging Tools
Drug-eluting stents should not be viewed as the definitive treatment for vulnerable plaque, according to David Holmes, MD, Mayo Clinic